IP Library Granted Patent US 8,450,364
Granted Patent B2
US 8,450,364 · App. 13/442,466 · Granted May 28, 2013

Use of equol for treating androgen mediated diseases

Inventors: Edwin Douglas Lephart (Orem, UT); Trent D. Lund (Wheaton, IL); Kenneth David Reginald Setchell (Cincinnati, OH); Robert J. Handa (Fort Collins, CO)
Assignees: Brigham Young University; Colorado State University Research Foundation; Children's Hospital Medical Center of Cincinnati, Ohio
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,450,364
App. No.
13/442,466
Granted
May 28, 2013
Kind
B2
Abstract

Equol (7-hydroxy-3(4′hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5α-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes.

Claims (21)

1. A method of reducing body weight in a subject in need thereof, comprising administering a non-racemic mixture of equol, wherein the equol consists of more than 50 percent R-equol to the subject.

2. A method of reducing leptin levels in a subject in need thereof, comprising administering a non-racemic mixture of equol, wherein the equol consists of more than 50 percent R-equol to the subject.

3. A method of increasing thyroid (T3) levels in a subject in need thereof, comprising administering a non-racemic mixture of equol, wherein the equol consists of more than 50 percent R-equol to the subject.

4. A method of decreasing a chronological-type of aging of skin or hair in a subject in need thereof, comprising administering a non-racemic mixture of equol, wherein the equol consists of more than 50 percent R-equol to the subject, wherein the decreasing the chronological-type of aging of skin or hair in the subject in need thereof comprises increasing antioxidant action in the skin, increasing collagen and elastin content, retaining or growing new scalp hair in female- and male-pattern baldness, or a combination thereof.

5. A method of reducing body weight in a subject in need thereof, comprising administering a composition for co-modulating androgen hormone actions and estrogen hormone action so as to ameliorate a condition in a subject, the composition comprising a non-racemic mixture of equol, wherein the equol consists of more than 50 percent R-equol to the subject.

6. A method of reducing leptin levels in a subject in need thereof, comprising administering a composition for co-modulating androgen hormone actions and estrogen hormone action so as to ameliorate a condition in a subject, the composition comprising a non-racemic mixture of equol, wherein the equol consists of more than 50 percent R-equol to the subject.

7. A method of increasing thyroid (T3) levels in a subject in need thereof, comprising administering a composition for co-modulating androgen hormone actions and estrogen hormone action so as to ameliorate a condition in a subject, the composition comprising a non-racemic mixture of equol, wherein the equol consists of more than 50 percent R-equol to the subject.

8. A method of decreasing a chronological-type of aging of skin or hair in a subject in need thereof, comprising administering a composition for co-modulating androgen hormone actions and estrogen hormone action so as to ameliorate a condition in a subject, the composition comprising a non-racemic mixture of equol, wherein the equol consists of more than 50 percent R-equol to the subject, wherein the decreasing the chronological-type of aging of skin or hair in the subject in need thereof comprises increasing antioxidant action in the skin, increasing collagen and elastin content, retaining or growing new scalp hair in female- and male-pattern baldness, or a combination thereof.

9. The method of claim 1 , wherein the equol is in a food product.

10. The method of claim 1 , wherein the equol is in a pharmaceutical.

11. The method of claim 1 , wherein the equol is in an over-the-counter medicament.

12. The method of claim 2 , wherein the equol is in a food product.

13. The method of claim 2 , wherein the equol is in a pharmaceutical.

14. The method of claim 2 , wherein the equol is in an over-the-counter medicament.

15. The method of claim 3 , wherein the equol is in a food product.

16. The method of claim 3 , wherein the equol is in a pharmaceutical.

17. The method of claim 3 , wherein the equol is in an over-the-counter medicament.

18. The method of claim 4 , wherein the equol is in a food product.

19. The method of claim 4 , wherein the equol is in a pharmaceutical.

20. The method of claim 4 , wherein the equol is in an over-the-counter medicament.

21. The method of claim 4 , wherein the equol is in a cosmetic.

Continuity (4)
Continuation 12572791 · Oct 2, 2009
Continuation 10533045
Provisional Application 60422469 · Oct 29, 2002
Related Publication 20120264821A1 · Oct 18, 2012